BIRC2 and neoplasm: Targeted BIRC2 knockdown, when combined with anti‐PD‐1 therapy, significantly suppressed tumour growth, enhanced CD8+ T cell infiltration, and amplified IFN‐γ and TNF‐α secretion in tumour models.